Iolyx Therapeutics Enters Strategic Agreement with Théa
Deal with Laboratoires Théa representing a total value of up to $280 million including clinical, regulatory and commercial conditional milestones, commercial royalties, and development responsibility for Phase 3 trials. Funds from concurrent Series B financing to support expansion of pipeline including retinal diseases BURLINGAME, Calif., December 3, 2025 — Iolyx Therapeutics, a clinical-stage biotechnology company focused on the […]
Sepul Bio, an innovative business unit of Théa, Doses First Participant in Phase 3 HYPERIONclinical trial of sepofarsen for CEP290-associated Leber Congenital Amaurosis Type 10
Clermont-Ferrand, France, Wednesday 1 October 2025 – Sepul Bio, an innovative business unit of Théa, dedicated to the advancement of RNA therapies for inherited retinal diseases, has today announced the dosing of its first participants in the Phase 3 HYPERION clinical trial for sepofarsen, in individuals with CEP290- associated Leber Congenital Amaurosis Type 10 (LCA10). “There are currently no […]